ACE2 and COVID-19: Neutralizing antibodies against the receptor binding domain (RBD) of the S1 subunit correlate with protection against COVID-19 as they prevent the binding of SARS-CoV-2 to human cells expressing angiotensin-converting enzyme 2 (ACE2) and subsequent entry into cells3.